BARCELONA — At the EuCornea meeting, Pavel Stodulka, MD, PhD, gives advice on how to solve a case in which the IOL falls down on the retina.
Uncategorized
Uncategorized
VIDEO: MLT beneficial treatment option for patients with open angle glaucoma
BARCELONA – At the ESCRS meeting, Jacky W. Y. Lee, MD, talks about micropulse laser trabeculoplasty as a treatment for open angle glaucoma. He also presents the results of a study with MLT performed at the University Eye Clinic of Hong Kong.
Uncategorized
Presbia Completes Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens™
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration announced that it has completed the second stage enrollment of its U.S. Food and Drug Administration (FDA) pivotal study, a significant milestone in the FDA approval process of its Presbia Flexivue Microlens™. In February, Presbia received FDA approval to commence the second stage pivotal study of its Microlens, which required enrollment of 337 qualified subjects. As the study
Uncategorized
Resumen: Novaliq GmbH refuerza su equipo de directores ejecutivos al nombrar a Oliver Schlüter, PhD, director general y financiero y a Hartmut Voss PhD, jefe de marca
HEIDELBERG, Alemania–(BUSINESS WIRE)–Novaliq GmbH, empresa farmacéutica especializada en estudios clínicos con una plataforma tecnológica puntera para la distribución de fármacos que transforma medicamentos poco solubles en terapias oftalmológicas efectivas, ha anunciado hoy que Oliver Schlüter, PhD, se ha unido a la compañía como director general y financiero, y que Hartmut Voss, PhD ha sido nombrado jefe de marca. El comunicado en el idioma original, es la versión oficial y autorizada del m
Uncategorized
Riassunto: Novaliq GmbH rafforza il team dirigenziale con le nomine di Oliver Schlüter, PhD, a direttore generale e direttore finanziario, e di Hartmut Voss, PhD, a CBO
HEIDELBERG, Germania–(BUSINESS WIRE)–Novaliq GmbH, società farmaceutica specializzata nella ricerca clinica con una piattaforma tecnologica per il rilascio dei farmaci in grado di trasformare ritrovati poco solubili in terapie oftalmiche efficaci, ha oggi annunciato che Oliver Schlüter, PhD, è entrato a far parte dell’azienda come direttore generale e direttore finanziario (CFO) e che Hartmut Voss, PhD, è il nuovo CBO (Chief Business Officer) dell’azienda. In precedenza il Dr. Schlüter ha ric
Uncategorized
Novaliq GmbH stärkt Managementteam mit der Ernennung von Dr. Oliver Schlüter zum Managing Director und CFO, und Dr. Hartmut Voss zum CBO
HEIDELBERG–(BUSINESS WIRE)–Die Novaliq GmbH, ein Unternehmen für pharmazeutische Spezialprodukte in der klinischen Entwicklung mit einer innovativen Drug Delivery-Plattform zur Formulierung schwerlöslicher aktiver pharmazeutischer Wirkstoffe für Anwendungen in der Ophthalmologie, hat heute bekannt gegeben, dass Dr. Oliver Schlüter dem Unternehmen als Managing Director und Chief Financial Officer (CFO) beigetreten ist. Dr. Hartmut Voss wurde zum Chief Business Officer (CBO) ernannt. Dr. Schlüt